Prevalence of Exposure to Potential CYP450 Pharmacokinetic Drug-Drug Interactions among Patients with Chronic Low Back Pain Taking Opioids

Joseph V. Pergolizzi, Sumedha A. Labhsetwar, R. Amy Puenpatom, Seongjung Joo, Rami H. Ben-Joseph, Kent H. Summers

Research output: Contribution to journalArticle

Abstract

Drug-drug interactions (DDIs) have been defined as two or more drugs interacting in such a way that the effectiveness and/or toxicity of one or all drugs are changed. Patients taking more than one drug metabolized through the cytochrome P450 (CYP450) enzyme system, including some, but not all, opioids experience a drug-drug exposure (DDE), which may result in a potentially dangerous DDI. Using a retrospective analysis of a large commercial claims database and a Medicare database, we evaluated DDEs that have the potential to cause DDIs among chronic low back pain (cLBP) patients on long-term opioid analgesia, which metabolizes through the CYP450 enzyme system, concomitant with other CYP450-metabolized drug(s). The overall prevalence of DDEs among cLBP patients was 27%. Women had a higher prevalence of DDEs (30.6% vs. 22% for men). Patients aged 45 to 55 and 56 to 64 years had the highest prevalence of DDEs (30.4% and 29.8%, respectively), followed by patients 34 to 45 years (27.9%). For patients>65 years, the prevalence of DDEs was 23.1%. In general, the prevalence of DDEs was fairly consistent across age ranges in this population. This study suggests that DDEs are common in the cLBP population. When selecting an opioid to treat cLBP, physicians should consider the potential for exposure of these patients to drugs that might unfavorably interact and, for that reason, the use of opioids that do not rely on the CYP450 system as their primary means of metabolism might be worthy of consideration.

Original languageEnglish (US)
Pages (from-to)230-239
Number of pages10
JournalPain Practice
Volume11
Issue number3
DOIs
StatePublished - May 2011

Fingerprint

Low Back Pain
Drug Interactions
Cytochrome P-450 Enzyme System
Dichlorodiphenyl Dichloroethylene
Opioid Analgesics
Pharmacokinetics
Pharmaceutical Preparations
Databases
Medicare
Analgesia
Population
Physicians

Keywords

  • Chronic low back pain
  • Drug-drug interaction
  • Opioids
  • Prevalence of drug interactions

ASJC Scopus subject areas

  • Anesthesiology and Pain Medicine

Cite this

Prevalence of Exposure to Potential CYP450 Pharmacokinetic Drug-Drug Interactions among Patients with Chronic Low Back Pain Taking Opioids. / Pergolizzi, Joseph V.; Labhsetwar, Sumedha A.; Puenpatom, R. Amy; Joo, Seongjung; Ben-Joseph, Rami H.; Summers, Kent H.

In: Pain Practice, Vol. 11, No. 3, 05.2011, p. 230-239.

Research output: Contribution to journalArticle

Pergolizzi, Joseph V. ; Labhsetwar, Sumedha A. ; Puenpatom, R. Amy ; Joo, Seongjung ; Ben-Joseph, Rami H. ; Summers, Kent H. / Prevalence of Exposure to Potential CYP450 Pharmacokinetic Drug-Drug Interactions among Patients with Chronic Low Back Pain Taking Opioids. In: Pain Practice. 2011 ; Vol. 11, No. 3. pp. 230-239.
@article{00725b4945c84adf886f22fb67b3ae81,
title = "Prevalence of Exposure to Potential CYP450 Pharmacokinetic Drug-Drug Interactions among Patients with Chronic Low Back Pain Taking Opioids",
abstract = "Drug-drug interactions (DDIs) have been defined as two or more drugs interacting in such a way that the effectiveness and/or toxicity of one or all drugs are changed. Patients taking more than one drug metabolized through the cytochrome P450 (CYP450) enzyme system, including some, but not all, opioids experience a drug-drug exposure (DDE), which may result in a potentially dangerous DDI. Using a retrospective analysis of a large commercial claims database and a Medicare database, we evaluated DDEs that have the potential to cause DDIs among chronic low back pain (cLBP) patients on long-term opioid analgesia, which metabolizes through the CYP450 enzyme system, concomitant with other CYP450-metabolized drug(s). The overall prevalence of DDEs among cLBP patients was 27{\%}. Women had a higher prevalence of DDEs (30.6{\%} vs. 22{\%} for men). Patients aged 45 to 55 and 56 to 64 years had the highest prevalence of DDEs (30.4{\%} and 29.8{\%}, respectively), followed by patients 34 to 45 years (27.9{\%}). For patients>65 years, the prevalence of DDEs was 23.1{\%}. In general, the prevalence of DDEs was fairly consistent across age ranges in this population. This study suggests that DDEs are common in the cLBP population. When selecting an opioid to treat cLBP, physicians should consider the potential for exposure of these patients to drugs that might unfavorably interact and, for that reason, the use of opioids that do not rely on the CYP450 system as their primary means of metabolism might be worthy of consideration.",
keywords = "Chronic low back pain, Drug-drug interaction, Opioids, Prevalence of drug interactions",
author = "Pergolizzi, {Joseph V.} and Labhsetwar, {Sumedha A.} and Puenpatom, {R. Amy} and Seongjung Joo and Ben-Joseph, {Rami H.} and Summers, {Kent H.}",
year = "2011",
month = "5",
doi = "10.1111/j.1533-2500.2010.00413.x",
language = "English (US)",
volume = "11",
pages = "230--239",
journal = "Pain Practice",
issn = "1530-7085",
publisher = "Wiley-Blackwell",
number = "3",

}

TY - JOUR

T1 - Prevalence of Exposure to Potential CYP450 Pharmacokinetic Drug-Drug Interactions among Patients with Chronic Low Back Pain Taking Opioids

AU - Pergolizzi, Joseph V.

AU - Labhsetwar, Sumedha A.

AU - Puenpatom, R. Amy

AU - Joo, Seongjung

AU - Ben-Joseph, Rami H.

AU - Summers, Kent H.

PY - 2011/5

Y1 - 2011/5

N2 - Drug-drug interactions (DDIs) have been defined as two or more drugs interacting in such a way that the effectiveness and/or toxicity of one or all drugs are changed. Patients taking more than one drug metabolized through the cytochrome P450 (CYP450) enzyme system, including some, but not all, opioids experience a drug-drug exposure (DDE), which may result in a potentially dangerous DDI. Using a retrospective analysis of a large commercial claims database and a Medicare database, we evaluated DDEs that have the potential to cause DDIs among chronic low back pain (cLBP) patients on long-term opioid analgesia, which metabolizes through the CYP450 enzyme system, concomitant with other CYP450-metabolized drug(s). The overall prevalence of DDEs among cLBP patients was 27%. Women had a higher prevalence of DDEs (30.6% vs. 22% for men). Patients aged 45 to 55 and 56 to 64 years had the highest prevalence of DDEs (30.4% and 29.8%, respectively), followed by patients 34 to 45 years (27.9%). For patients>65 years, the prevalence of DDEs was 23.1%. In general, the prevalence of DDEs was fairly consistent across age ranges in this population. This study suggests that DDEs are common in the cLBP population. When selecting an opioid to treat cLBP, physicians should consider the potential for exposure of these patients to drugs that might unfavorably interact and, for that reason, the use of opioids that do not rely on the CYP450 system as their primary means of metabolism might be worthy of consideration.

AB - Drug-drug interactions (DDIs) have been defined as two or more drugs interacting in such a way that the effectiveness and/or toxicity of one or all drugs are changed. Patients taking more than one drug metabolized through the cytochrome P450 (CYP450) enzyme system, including some, but not all, opioids experience a drug-drug exposure (DDE), which may result in a potentially dangerous DDI. Using a retrospective analysis of a large commercial claims database and a Medicare database, we evaluated DDEs that have the potential to cause DDIs among chronic low back pain (cLBP) patients on long-term opioid analgesia, which metabolizes through the CYP450 enzyme system, concomitant with other CYP450-metabolized drug(s). The overall prevalence of DDEs among cLBP patients was 27%. Women had a higher prevalence of DDEs (30.6% vs. 22% for men). Patients aged 45 to 55 and 56 to 64 years had the highest prevalence of DDEs (30.4% and 29.8%, respectively), followed by patients 34 to 45 years (27.9%). For patients>65 years, the prevalence of DDEs was 23.1%. In general, the prevalence of DDEs was fairly consistent across age ranges in this population. This study suggests that DDEs are common in the cLBP population. When selecting an opioid to treat cLBP, physicians should consider the potential for exposure of these patients to drugs that might unfavorably interact and, for that reason, the use of opioids that do not rely on the CYP450 system as their primary means of metabolism might be worthy of consideration.

KW - Chronic low back pain

KW - Drug-drug interaction

KW - Opioids

KW - Prevalence of drug interactions

UR - http://www.scopus.com/inward/record.url?scp=79955576117&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79955576117&partnerID=8YFLogxK

U2 - 10.1111/j.1533-2500.2010.00413.x

DO - 10.1111/j.1533-2500.2010.00413.x

M3 - Article

C2 - 20807350

AN - SCOPUS:79955576117

VL - 11

SP - 230

EP - 239

JO - Pain Practice

JF - Pain Practice

SN - 1530-7085

IS - 3

ER -